Activity of T-DM1 in Her2-positive breast cancer brain metastases-Reference-Cited by-同舟云学术

Activity of T-DM1 in Her2-positive breast cancer brain metastases

Published:2015-08-25 Issue:7 Volume:32 Page:729-737
ISSN:0262-0898
Container-title:Clinical & Experimental Metastasis
language:en
Short-container-title:Clin Exp Metastasis

Author:

Bartsch Rupert,Berghoff Anna S.,Vogl Ursula,Rudas Margaretha,Bergen Elisabeth,Dubsky Peter,Dieckmann Karin,Pinker Katja,Bago-Horvath Zsuzsanna,Galid Arik,Oehler Leopold,Zielinski Christoph C.,Gnant Michael,Steger Guenther G.,Preusser Matthias

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10585-015-9740-3.pdf

Reference23 articles.

1. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Goncalves A, Leheurteur M, Domont J, Gutierrez M, Cure H, Ferrero JM, Labbe-Devilliers C (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14(1):64–71. doi: 10.1016/S1470-2045(12)70432-1

2. Bartsch R, De Vries C, Pluschnig U, Dubsky P, Bago-Horvath Z, Gampenrieder SP, Rudas M, Mader RM, Rottenfusser A, Wiltschke C, Gnant M, Zielinski CC, Steger GG (2009) Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. BMC Cancer 9:367. doi: 10.1186/1471-2407-9-367

3. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG (2012) Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 106(1):25–31. doi: 10.1038/bjc.2011.531

4. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972–2977. doi: 10.1002/cncr.11436

5. Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106(3):440–446. doi: 10.1038/bjc.2011.597

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022;Annals of Oncology;2024-07

2. Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis;npj Breast Cancer;2024-06-13

3. Trastuzumab Deruxtecan in brain metastases from breast cancer: outcome analysis of real life population;2024-06-11

4. Breast Cancer Brain Metastasis: A Comprehensive Review;JCO Oncology Practice;2024-05-15

5. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial;ESMO Open;2024-05